Six poster presentations highlight CARVYKTI® efficacy, safety, and real-world outcomes across CARTITUDE trials and analyses, reflecting a ...

Following its recent $16.5 million Series A financing in December, Ember LifeSciences, Inc., a leading provider of revolutionary cold chain technology, announced the appointment of Ann Hyllengren as ...

Wugen, Inc., a clinical-stage biotechnology company developing allogeneic, off-the-shelf cell therapies for the treatment of hematological malignancies, today announced that it has received ...